Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R (Q30357731)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R
scientific article

    Statements

    Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R (English)
    0 references
    0 references
    0 references
    0 references
    Stefan S Bielack
    Sigbjørn Smeland
    Jeremy S Whelan
    Zsuzsanna Pápai
    Claudia Deffenbaugh
    Rajaram Nagarajan
    Bernadette Brennan
    G Douglas Letson
    Daniel Baumhoer
    Mathias Werner
    Kirsten Sundby Hall
    Mikael Eriksson
    Paula Schomberg
    Henk van den Berg
    Marleen Renard
    Peter Reichardt
    Trude Butterfass-Bahloul
    Beatrice Seddon
    Gabriele Calaminus
    Maria Michelagnoli
    Catharina Dhooge
    Mark Bernstein
    EURAMOS-1 investigators

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit